Stocks · Healthcare · Biotechnology

Boundless Bio, Inc. BOLD

$2.62 +1.16% Close, Oct 2, 2026 · NASDAQ · Market cap $58.9M

Strong trendExpensive vs sector

Next earnings report: Nov 5, 2026

Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.

Three things to know

  1. Over the past year the stock returned +113.0%, ahead of the S&P 500 by 97.9 percentage points.
  2. The stock is in an uptrend: above its 200-day average for 121 trading days, with the 50-day average above the 200-day.
  3. The company holds net cash of $20.2M (cash above total debt).

PromtFinance scores

Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.

Growth—Not enough data

How fast revenue, earnings and cash flow are growing.

Quality28Very weak

Returns on capital, margins, earnings quality and balance-sheet strength.

  • Return on invested capitalBottom 10%
  • Accruals (lower is better)Top 33%
Value1Very weak

How cheap the shares are relative to earnings, cash flow and their own history.

  • Earnings yieldBottom 5%
  • Free-cash-flow yieldBottom 3%
  • EBITDA / enterprise valueBottom 3%
Momentum90Exceptional

Strength and persistence of the price trend, including versus the S&P 500.

  • 12-month return excluding last monthTop 12%
  • 6-month returnTop 4%
  • 1-year return vs S&P 500Top 13%
  • Distance from 52-week highTop 26%
  • Trend checklist (0–4)Top 39%
Revisions1Very weak

Earnings surprises and analyst sentiment (estimate-revision history is being collected).

  • Average EPS surprise, last 4 quartersBottom 22%
  • Consecutive EPS beatsBottom 20%
  • Share of analysts rating BuyBottom 3%
Stability51Neutral

Low volatility, shallow drawdowns, low market sensitivity and modest leverage.

  • Volatility, 60 days (lower is better)Top 12%
  • Maximum drawdown, 3 yearsBottom 9%
  • Beta vs S&P 500 (lower is better)Bottom 48%

Fundamental momentum

MeasureNow (TTM)Year / quarter beforeSector rank
Return on invested capital-103.1%—Bottom 10%

Quality of earnings and balance sheet

Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
-10.5%
Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
Net cash

Shareholder returns

Dividend yield (dividends paid, TTM)
0.00%
Net buyback yield (TTM)
-0.16%
Shareholder yield
-0.16%
Share count change, 1 year
+0.4%
Share count change, 3-year CAGR
+0.3%

Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.

Based on the four quarters through Jun 30, 2026 (filed Aug 7, 2026).

Earnings and expectations

Earnings momentum

Consecutive EPS beats
0
Beats in the last 8 reports
2 of 8
Average EPS surprise, last 4
-16.6%
Average 2-day reaction, last 8
-0.5%
Positive 20 days after report
3 of 8

Analysts

Analysts with a rating
20
Share rating Buy or Strong Buy
30%
Consensus rating
Hold

How the stock reacted to recent reports

Report dateEPS surprise2 days5 days20 days60 days
Aug 4, 2026+0.0%+5.4%+9.7%+9.3%—
May 8, 2026-17.6%-5.9%+1.3%-7.2%+77.1%
Mar 9, 2026-31.8%+0.9%-1.8%+4.4%+26.5%
Nov 5, 2025-17.0%-3.1%-3.1%-16.9%-13.1%
Aug 5, 2025+6.7%-1.7%-7.5%-4.2%+21.7%
May 9, 2025-4.4%-4.0%+12.7%-21.3%-21.3%
Mar 27, 2025+0.0%-0.7%-2.0%+1.3%-32.2%
Nov 7, 2024+2.6%+4.7%+12.6%-19.9%-21.1%

Returns from the close before each report. Past reactions do not determine future ones.

Earnings history

Report dateEPSEstimateSurpriseRevenue
Aug 4, 2026-$1.06-$1.06+0.0%—
May 8, 2026-$0.60-$0.51-17.6%—
Mar 9, 2026-$0.58-$0.44-31.8%—
Nov 5, 2025-$0.62-$0.53-17.0%—
Aug 5, 2025-$0.70-$0.75+6.7%—
May 9, 2025-$0.71-$0.68-4.4%—
Mar 27, 2025-$0.74-$0.74+0.0%—
Nov 7, 2024-$0.74-$0.76+2.6%—

Valuation in context

MultipleNow5-year median5-year percentileSector rank (cheapness)
Free-cash-flow yield-96.35%——Bottom 3%
Earnings yield-109.16%——Bottom 5%

Technical state

Trend checklist

  • ✗ Price above 20-day average
  • ✗ Price above 50-day average
  • ✓ Price above 200-day average
  • ✓ 50-day average above 200-day
  • ✗ MACD histogram positive

Trend quality

Days above the 50-day average
0
Days above the 200-day average
121
50-day average slope (20 days)
+3.9%
200-day average slope (20 days)
+9.9%
Distance from 50-day average
-5.1%
Distance from 200-day average
+46.4%
RSI (14)
41.8
Relative volume
1.16×

Risk and drawdowns

Volatility, 60 days (annualized)
31.6%
Volatility vs own 5-year history
2th percentile · Low for this stock
Beta vs S&P 500 (2 years, weekly)
1.14
Correlation with S&P 500
0.21
Current drawdown from 1-year high
-12.7%
Maximum drawdown, 3 years
-92.9%

Largest declines in the past six years

From peakTo lowDeclineLengthRecovery
Mar 28, 2024Jun 27, 2025-92.9%312 daysNot yet recovered

Declines of 10% or more from a closing high, measured on daily closes.

Financial statements

Market cap
$58.9M
EPS, diluted (TTM)
-$2.86
Revenue (TTM)
$0
52-week range
$0.96 – $3.16
FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$0$0$0$0$0
Gross profit$0$0$0-$1.1M-$1.3M
Operating income-$25.3M-$46.5M-$54.8M-$73.3M-$63.6M
Net income-$25.2M-$45.9M-$49.4M-$65.4M-$58.2M
EPS (diluted)-$1.13-$2.06-$2.22-$3.85-$2.60
Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue$0$0$0$0$0$0$0$0
Net income-$16.5M-$16.4M-$15.8M-$15.7M-$13.9M-$12.9M-$13.6M-$23.7M
EPS (diluted)-$0.74-$0.84-$0.71-$0.70-$0.62-$0.58-$0.60-$1.06
FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow-$23.2M-$39.6M-$46.9M-$60.8M-$46.7M
Capital expenditure-$2.0M-$1.1M-$633,000-$2.5M-$546,000
Free cash flow-$25.3M-$40.7M-$47.5M-$63.4M-$47.2M
Dividends paid$0$0$0$0$0
Net share buybacks$0$126,000$0$93.0M$141,000

Cash outflows are shown as negative numbers.

Cash and short-term investments
$72.6M
Total assets
$73.7M
Total liabilities
$7.8M
Total debt
$0
Net debt
-$20.2M
Shareholders’ equity
$66.0M

As of Jun 30, 2026 (filed Aug 7, 2026).

Short interest

Shares sold short
811,956
Days to cover
12.20
Change vs previous report
-0.2%

FINRA short interest, settlement date Sep 15, 2026.